Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EBT (2017 - 2025)

Historic EBT for Lexaria Bioscience (LEXX) over the last 12 years, with Q4 2025 value amounting to -$1.6 million.

  • Lexaria Bioscience's EBT rose 4151.63% to -$1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$10.8 million, marking a year-over-year decrease of 4745.27%. This contributed to the annual value of -$11.9 million for FY2025, which is 10697.15% down from last year.
  • Lexaria Bioscience's EBT amounted to -$1.6 million in Q4 2025, which was up 4151.63% from -$2.7 million recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's EBT ranged from a high of -$668006.0 in Q1 2024 and a low of -$3.8 million during Q2 2025
  • In the last 5 years, Lexaria Bioscience's EBT had a median value of -$1.7 million in 2024 and averaged -$1.9 million.
  • Per our database at Business Quant, Lexaria Bioscience's EBT surged by 4953.21% in 2024 and then tumbled by 31182.44% in 2025.
  • Quarter analysis of 5 years shows Lexaria Bioscience's EBT stood at -$2.0 million in 2021, then grew by 15.38% to -$1.7 million in 2022, then surged by 33.24% to -$1.1 million in 2023, then crashed by 137.73% to -$2.7 million in 2024, then skyrocketed by 41.52% to -$1.6 million in 2025.
  • Its EBT was -$1.6 million in Q4 2025, compared to -$2.7 million in Q3 2025 and -$3.8 million in Q2 2025.